The week of March 23-27, 2026, was defined by geopolitical tensions shaping industry policy, a resurgence in high-value M&A, and critical clinical data that delineated winners from losers. A senior U.S. health official framed competition with China in existential terms 1, even as the industry pushed back against the FDA's proposed "America First" fee structures 2. Meanwhile, multibillion-dollar deals for Merck) and Recordati signaled robust appetite for strategic assets, while clinical setbacks in obesity and successes in ophthalmology and rare disease underscored the sector's high-stakes, binary nature [Source 3, Source 6, Source 7, Source 21].
Key Developments
Geopolitics and Policy Take Center Stage
The most striking rhetoric of the week came from Chris Klomp, a senior HHS official and head of Medicare, who declared competition with China’s ascending biotech industry “a war” during a speech at the Conservative Political Action Conference 1. This sentiment dovetailed with ongoing policy friction, as biopharma industry representatives challenged the FDA’s proposals for the next user fee agreements, which included limiting small business waivers to only U.S. applicants—a move viewed as overly political 2. Concurrently, corporate strategy reflected the global landscape: Boehringer Ingelheim board chairman Shashank Deshpande noted the company could look at China-based companies for dealmaking 17, while an AbbVie executive was reported to be visiting China 4.
M&A Activity Reaches a Fever Pitch
Mergers and acquisitions made major headlines, led by Merck’s $6.7 billion cash acquisition of Terns Pharmaceuticals. The deal grants Merck an investigational treatment for chronic myeloid leukemia that could potentially challenge Novartis' Scemblix 22. Across the Atlantic, Milan-based Recordati confirmed it had received a takeover bid exceeding $12 billion from private equity firm CVC Capital Partners 3. These massive transactions highlight a renewed focus on bolstering pipelines through strategic purchases.
Clinical Triumphs and a High-Profile Setback
The clinical arena delivered clear-cut outcomes. Kodiak Sciences reported a Phase 3 success for its eye drug Zenkuda (tarcocimab tedromer), which beat a sham procedure in patients with retinal vascular disease 7. In rare disease, Beam Therapeutics presented promising data for its base editing therapy for alpha-1 antitrypsin deficiency (AATD), prompting plans to seek an accelerated approval pathway 16. Maze Therapeutics also unveiled positive Phase 2 data for its kidney disease drug MZE829, positioning it as a potential competitor to a Vertex program targeting the same disease 20.
However, the week also served as a reminder of the steep challenges in obesity drug development. Wave Life Sciences saw its non-GLP-1 obesity candidate crash on clinical disappointment, underscoring the difficulty of competing in this lucrative field with alternative mechanisms 6.
Market Movers
The significant M&A news directly impacted the involved companies. Merck's multi-billion dollar purchase of Terns Pharmaceuticals is a major strategic investment in its oncology division 22. While specific stock movements are not detailed in the sources, the confirmed $12 billion+ bid for Recordati places the Italian firm squarely in the spotlight as a major acquisition target 3.
Get Weekly Biotech Insights
Join thousands of investors and researchers who stay ahead with our free weekly newsletter.
Our database context shows the immense scale of the global biopharma market, with tracked companies holding a combined market cap of $213.77 trillion. The top players by market cap, led by Samsung Biologics ($74.11T) and Celltrion ($44.19T), highlight the significant financial heft concentrated in large Asian biopharma and CDMO firms, providing backdrop to the geopolitical tensions noted this week.
Regulatory Updates
The FDA had a notably active week, issuing several key decisions. Corcept Therapeutics received an approval months ahead of schedule for Lifyorli in combination with nab-paclitaxel to treat three types of ovarian cancer 14. In a significant win for the rare disease sector, Denali Therapeutics secured an accelerated approval for its drug Avlayah (tividenofusp), bucking a recent trend of rejections in that space 21.
The regulatory landscape for future products was also a topic of discussion, with Beam Therapeutics laying the groundwork to seek accelerated approval for its AATD base editor following promising clinical updates 16. Conversely, Ocugen) is proceeding to Phase 3 with its geographic atrophy gene therapy despite mixed earlier results, indicating a regulatory path remains open 23.
Looking Ahead
Several stories from this week set the stage for important developments in the coming months. The political debate around the FDA's user fee proposals and "America First" policies is likely to intensify as industry pushback continues 2. The future of the Advisory Committee on Immunization Practices (ACIP) may come into question following social media suggestions from former member Robert Malone that the group could be disbanded 9.
In the clinic, all eyes will be on Seaport Therapeutics as it advances its Phase 2b depression trial for SPT-300, which includes a built-in fail-safe to pivot to a different patient population if needed 13. The competitive landscape in kidney disease will heat up as Maze Therapeutics advances its promising candidate against Vertex 20, and the race to deliver GLP-1 drugs via novel methods will continue, fueled by a $50 million raise for a microneedle patch company pivoting to this delivery challenge 19. Finally, Takeda will enter a new era as incoming CEO Julie Kim implements the next steps in the company's multi-year restructuring plan 11.